Everything You Need to Know About The Top 5 Companies Operating in Global mRNA Vaccines and Therapeutics Market

The Global mRNA Vaccines and Therapeutics Market is highly competitive in nature. Numerous companies are striving to solidify their position in this vast industry.

Here are the top 5 companies that are characterizing the competitive terrain of this industry sphere-

Moderna, Inc.

Market Position or History

• In March 2013, Moderna Inc. inked an agreement deal with AstraZeneca. Under this agreement, the companies will jointly work towards the discovery, launch, and commercialization of messenger RNA therapeutics to facilitate the treatment of various renal, metabolic, and cardiovascular ailments. The company reportedly invested around USD 180 million in this project.
• On December 18, 2020, the COVID-19 vaccine developed by Moderna Inc. was approved for emergency use by the US Food and Drug Administration (FDA). Post that, various other health-based organizations like WHO authorized the Vaccine for mass inoculation.

Business Overview and Strategy

Founded in September 2010, Moderna Inc. has emerged as one of the pioneering companies in the pharmaceutical and biotechnology sector. It is based in Cambridge; Massachusetts and its product portfolio predominantly comprises of RNA therapeutics. It is the first company to revolutionize the drug development sector through the use of RNA therapeutics for efficient disease diagnosis and treatment.

The prime goal of the company is to target diseases that cannot be cured by existing drugs. Its broad product pipeline comprises of 125 patent fills and 6,500 claims. It ranges from specific drug compositions to novel nucleotide chemistries mainly aimed at treating rare diseases. Most of the drugs produced by the company are equipped with the ability to produce antibodies and proteins inside the target cells of a patient. Moderna, Inc. has collaborated and partnered with prime biotech companies to diversify its offerings. It is striving to find potential cure for rare diseases by boosting its R&D activities in a massive scale.

CureVac N.V.

Major Position or History

• In May 2022, CureVac N.V. inked a partnership deal with myNEO with an aim to diversify its oncology diagnostics and therapeutics pipeline. As a part of this agreement, both these companies will join hands to facilitate the accurate identification of specific antigens that are found on the surface of various tumours. This in turn will enable them to develop mRNA immunotherapies to treat various forms of cancer.
• In June 2022, CureVac N.V. announced the acquisition of Frame Cancer Therapeutics with an aim to boost its cancer research and oncological drug development portfolio.

Business Overview and Strategy

CureVac N.V. was established in 2000 by Steve Pascolo, Ingmar Hoerr, Florian von der Mulbe, Günther Jung, and Hans-Georg Rammensee. It is headquartered in Tubingen, Germany and is primarily known for developing messenger RNA based therapies. The prime focus of the company is to work towards the development of efficient vaccines to prevent a wide array of infectious diseases. It has also added cancer and rare diseases to its therapeutics portfolio. Its product pipeline mainly constitutes of cancer immunotherapies, prophylactic vaccines, and molecular therapies.

CureVac N.V. has accelerated its R&D activities to leverage its existing drug development technologies to formulate live saving therapeutics for deadly diseases like cancer. It further collaborates with prominent companies and healthcare organizations to scale up its development activities.

Translate Bio, Inc.

Market Position or History

• In September 2021, Translate Bio, Inc. was acquired by Sanofi, a prominent biotechnological company for USD 3.2 billion.

Business Overview and Strategy

Headquartered in Lexington, Massachusetts, Translate Bio, Inc. was established in 2011. After the acquisition, it has been operating as a Subsidiary of Sanofi. The company pioneers in developing transformative drugs to cure disease triggered by the dysfunction of gene and protein inside the body. The therapeutics produced by the company mostly function by generating protective immunity inside a patient’s body.

The product pipeline of the company comprises of vaccines and therapeutics pertaining to various rare and genetic diseases. Its predominant focus is to translate RNA science into efficient therapeutics for ailments caused by insufficient protein product inside the body.

BioNTech SE

Market Position or History

• In August 2018, BioNTech SE joined hands with Pfizer Inc. by signing a multi-year R&D collaboration agreement. Under the terms of the deal, both the companies will make use of their existing resources to develop mRNA-based influenza vaccines.
• In October 2022, BioNTech SE inked a collaboration deal with State of Victoria, Australia. Under this deal, the duo intends to establish a research and innovation center in Melbourne to develop mRNA-based vaccines and therapies based on the academic research works conducted by the company.

Business Overview and Strategy

Based in Mainz, Germany, the company was established in 2008. The therapeutics produced by BioNTech SE are based on patient-centric approaches. The product pipeline of the company includes mRNA based cancer immunotherapies, vaccines for infectious diseases, novel antibodies, small molecule immunomodulators, protein replacement therapies, as well as cell therapies. The drugs and therapies mostly target genetic disorders, cancer, and a wide array of infectious diseases.

The company emphasizes on enhancing its R&D activities by integrating innovative technologies. It further formulates effective strategies to include the existing research based or technology based entities of other biotechnology companies to improve its drug/therapeutics discovery and development process.

Sangamo Therapeutics, Inc.

Market Position or History

• On December 2018, Sangamo Therapeutics, Inc. announced the complete acquisition of TxCell with an aim to enhance its offerings in the CAR-Treg based therapeutics vertical.
• In July 2020, Sangamo inked a collaboration deal with Norvartis. Under this agreement, both the companies with work towards the development and commercialization of gene regulation therapies for neurodevelopmental disorders.

Business Overview and Strategy

Based in Brisbane, California, Sangamo Therapeutics, Inc. was established in 1995 by Edward O Lanphier II. It predominantly aims towards the development of advanced therapeutics to treat deadly genetic disorders. It mainly concentrates on the use of gene and cell therapy to facilitate the treatment of genetic diseases.

The primary therapeutic technology pipeline of this company are gene therapy, genome editing, cell therapy, and gene regulation. Sangamo Therapeutics has been updating its drug development dynamics by integrating advanced technologies in the sector. In fact, it is the first ever biotechnology company to focus on the use of the zinc finger technology to develop efficient genome-based cure for patients affected with diseases like Haemophilia A.